[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100069145":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":7,"locations":7,"responsibleParty":7,"collaborators":7,"id":16,"slug":17,"hasResults":18,"nctId":19,"briefTitle":20,"officialTitle":21,"acronym":7,"eligibilityCriteria":22,"healthyVolunteers":18,"sex":23,"minAge":24,"maxAge":7,"enrollmentInfo":25,"targetDuration":7,"studyType":27,"phases":28,"briefSummary":30,"conditions":31,"keywords":33,"overallStatus":35,"whyStopped":7,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":45,"locationsCount":7},{"fullName":5,"class":6},"UCB Pharma","INDUSTRY",null,[9],{"type":10,"name":11,"description":7,"armGroupLabels":7,"otherNames":7},"DRUG","Certolizumab Pegol (CDP870)",[13],{"name":14,"affiliation":5,"role":15},"UCB Clinical Trial Call Center","STUDY_DIRECTOR","100069145","phase-3-study-to-test-the-effect-of-cdp870-in-the-treatment-of-crohns-disease-over-26-weeks-comparing-cdp870-to-a-dummy-drug-placebo-following-3-doses-of-active-drug-cdp870-100069145",false,"NCT00152425","Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).","A Phase III Multi-national, Multi-centre, Double-blind Placebo-controlled Parallel Group, 26 Week Study to Assess the Maintenance of Clinical Response to Humanised Anti-TNF PEG Conjugate, CDP870 400 mg sc, (Dosed 4-weekly From Weeks 8 to 24), in the Treatment of Patients With Active Crohn's Disease Who Have Responded to Open Induction Therapy (Dosed at Weeks 0, 2 and 4) With CDP870","Inclusion Criteria:\n\n* Definitive diagnosis of Crohn's disease confirmed (at least 3 months prior to study entry) either by radiological, endoscopic or histological evidence, affecting the terminal ileum (L1), colon (L2) or ileocolon (L3)\\*. \\* Vienna Classification (1998)\n* Active Crohn's disease (≥ 220 and ≤ 450) scored over the 7 days prior to the first dose of study drug.\n* Patients aged 18 years or above at screening.\n\nExclusion Criteria:\n\n* Crohn's Disease Related\n* Fistula abscess present at screening.\n* Stricturing type disease with symptoms or signs of non-inflammatory mechanical obstruction or bowel perforation in last 3 months.\n* Short bowel syndrome.\n* Functional colostomy or ileostomy (note: patients who have had a temporary stoma in the past, which has been reversed, are eligible to enter the study).\n* Positive stool laboratory results for enteric pathogens.","ALL","18 Years",{"count":26,"type":7},392,"INTERVENTIONAL",[29],"PHASE3","A 26 week maintenance study of CDP870 in Crohn's disease",[32],"Crohn's Disease",[34],"Crohn's disease, CDP870, CDAI, clinical response, remission, Certolizumab Pegol, Cimzia","COMPLETED","2013-09-06",{"date":38,"type":39},"2013-09-09","ESTIMATED",{"date":41,"type":7},"2004-02",{"date":43,"type":44},"2005-05","ACTUAL",{"name":5,"class":6}]